Literature DB >> 16091237

Management of occupational and nonoccupational postexposure HIV prophylaxis.

Mitchell H Katz1, Julie Louise Gerberding.   

Abstract

The principles of managing patients with recent HIV exposures are similar whether the exposure occurs in an occupational or nonoccupational setting. For both settings, clinicians should 1) assess the likelihood that HIV and other bloodborne viruses will be transmitted as a consequence of the exposure; 2) advise the patient about the risks and benefits of treatment; 3) choose an appropriate antiretroviral treatment regimen (if the decision is made to treat); 4) screen for other illnesses that may complicate treatment or follow-up; 5) counsel patients about the importance of adhering to treatment; 6) promote safe-sex practices and methods to avoid future exposures; 7) follow the patient for potential side effects of treatment; 8) provide follow-up care including repeat HIV testing for seroconversion, surveillance for primary HIV infection, and reinforcement of counseling messages.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 16091237     DOI: 10.1007/s11904-004-0025-8

Source DB:  PubMed          Journal:  Curr HIV/AIDS Rep        ISSN: 1548-3568            Impact factor:   5.495


  46 in total

1.  Postexposure prophylaxis for human immunodeficiency virus infection after sexual or injection drug use exposure: identification and characterization of the source of exposure.

Authors:  M E Roland; J N Martin; R M Grant; N S Hellmann; J D Bamberger; M H Katz; M Chesney; K Franses; T J Coates; J O Kahn
Journal:  J Infect Dis       Date:  2001-12-03       Impact factor: 5.226

2.  HIV postexposure prophylaxis for children and adolescents.

Authors:  F E Babl; E R Cooper; B Damon; T Louie; S Kharasch; J A Harris
Journal:  Am J Emerg Med       Date:  2000-05       Impact factor: 2.469

3.  Short-term interferon-alfa therapy for acute hepatitis C: a randomized controlled trial.

Authors:  Hideyuki Nomura; Suketo Sou; Hironori Tanimoto; Takashi Nagahama; Yoichi Kimura; Jun Hayashi; Hiromi Ishibashi; Seizaburo Kashiwagi
Journal:  Hepatology       Date:  2004-05       Impact factor: 17.425

4.  Infectiousness of HIV between male homosexual partners.

Authors:  V DeGruttola; G R Seage; K H Mayer; C R Horsburgh
Journal:  J Clin Epidemiol       Date:  1989       Impact factor: 6.437

Review 5.  Prophylaxis for occupational exposure to HIV.

Authors:  J L Gerberding
Journal:  Ann Intern Med       Date:  1996-09-15       Impact factor: 25.391

6.  Needlestick transmission of hepatitis C.

Authors:  Mark S Sulkowski; Stuart C Ray; David L Thomas
Journal:  JAMA       Date:  2002-05-08       Impact factor: 56.272

7.  3'-Azido-3'-deoxythymidine in feline leukemia virus-infected cats: a model for therapy and prophylaxis of AIDS.

Authors:  L Tavares; C Roneker; K Johnston; S N Lehrman; F de Noronha
Journal:  Cancer Res       Date:  1987-06-15       Impact factor: 12.701

8.  Post-exposure prophylaxis after non-occupational HIV exposure: impact of recommendations on physicians' experiences and attitudes.

Authors:  Anne Laporte; Nathalie Jourdan; Elisabeth Bouvet; Franck Lamontagne; Josiane Pillonel; Jean-Claude Desenclos
Journal:  AIDS       Date:  2002-02-15       Impact factor: 4.177

Review 9.  The estimated prevalence and incidence of HIV in 96 large US metropolitan areas.

Authors:  S D Holmberg
Journal:  Am J Public Health       Date:  1996-05       Impact factor: 9.308

10.  Pegylated interferon alpha therapy in acute hepatitis C: relation to hepatitis C virus-specific T cell response kinetics.

Authors:  Sanaa M Kamal; Alaa Ismail; Camilla S Graham; Qi He; Jens W Rasenack; Thomas Peters; Ahmed A Tawil; Jutta J Fehr; Khalifa El Sayed Khalifa; Mahmoud M Madwar; Margaret James Koziel
Journal:  Hepatology       Date:  2004-06       Impact factor: 17.425

View more
  1 in total

Review 1.  The acute HIV infection: implications for intervention, prevention and development of an effective AIDS vaccine.

Authors:  Yoshiaki Nishimura; Malcolm A Martin
Journal:  Curr Opin Virol       Date:  2011-09       Impact factor: 7.090

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.